6:49 PM
 | 
Mar 07, 2008
 |  BC Extra  |  Company News

Gilead submits aztreonam MAA

Gilead (NASDAQ:GILD) submitted an MAA to EMEA for aztreonam lysine for inhalation to treat cystic fibrosis (CF) patients who...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >